Arifon Retard film-coated tablets of prolonged action 1.5 mg 30 pcs.

The active substance is indapamine (one tablet contains 1.5 mg of indapamide).

Excipients: lactose monohydrate, hypromellose (E 464), povidone, colloidal anhydrous silicon dioxide (E 551), magnesium stearate (E 470 B), titanium dioxide (E 171), glycerol (E 422), macrogol 6000.

• hypersensitivity to the active substance, other sulfonamides or to any excipients;
• severe renal failure;
• hepatic encephalopathy or severe liver dysfunction;
• hypokalemia.

For oral use.

Dosage – one tablet per day, preferably in the morning. The tablet should be swallowed whole, without chewing, with water.

The use of higher doses of the drug does not lead to an increase in the antihypertensive effect, but the diuretic effect increases.

Pregnant women

Data on the use of indapamide in pregnant women are absent or limited (less than 300 cases). The consequence of prolonged use of thiazide diuretics during the third trimester of pregnancy may be a decrease in the volume of circulating blood of the pregnant woman and uteroplacental blood flow, which may lead to fetoplacental ischemia and fetal growth retardation. As a precautionary measure, it is advisable to avoid the use of indapamide during pregnancy.

There is insufficient data on the excretion of indapamide/metabolites into breast milk. Indapamide should not be used during breast-feeding.

No effect on human fertility is expected.

Children

The safety and effectiveness of the drug in children have not been established.

Drivers

The drug “Arifon Retard” does not affect alertness. However, in the event of adverse reactions, including symptoms associated with a decrease in blood pressure, especially at the beginning of treatment or when used in combination with another antihypertensive agent, the ability to drive a car or operate other mechanisms may be impaired.

Symptoms

Symptoms of overdose are primarily manifestations of water and electrolyte disorders (hyponatremia, hypokalemia). Clinically, nausea, vomiting, hypotension, convulsions, drowsiness, dizziness (vertigo), confusion, polyuria or oliguria up to anuria (caused by hypovolemia) are possible.

Treatment

First aid measures include rapid removal of the drug by gastric lavage and/or administration of activated charcoal, followed by restoration of water and electrolyte balance in a hospital setting.

The most frequently reported adverse reactions were: hypersensitivity reactions, mainly dermatological, in patients predisposed to allergic and asthmatic reactions, and maculopapular rashes.

Store at a temperature not exceeding 30 °C, out of the reach of children.

Shelf life – 2 years.